Breviscapine is a natural compound extracted from Erigeron Breviscapus (Vant.) Hand.-Mazz., which is a Chinese herbal medicine that has been in use for the treatment of paralysis, rheumatism, gastritis, toothache, and fever for more than 600 years. It has been found only in China, in the provinces of Guangxi, Guizhou, Hunan, Sichuan, Tibet, and Yunnan.
Breviscapine is a crude extract of several ﬂavonoids of Erigeron breviscapus.
Our breviscapine contains more than 98% of scutellarin, which has been traditionally used in China as an activating blood circulation medicine to improve cerebral blood supply.
The use of breviscapine for the treatment of hypertension, cerebral embolism, and paralysis due to cerebrovascular accident dates back to the 1970s. Recent studies have suggested that breviscapine can be used to treat cerebral infarction and diabetic nephropathy.
ACTIVE COMPOUNDS IN BREVISCAPINE
As the primary active ingredient in Breviscapine, scutellarin’s (4′,5,6,7-tetrahydroxyflavone-7-O-glucuronide) increases cerebral blood flow. Studies have shown that it raises permeability of blood-brain barrier, increases nutritional blood flow of myocardium, raises immune function of body macrophage cell and counteraction against blood and oxygen depletion induced by hypophyseal pituitrin and thrombocyte agglutination.
Apigenin Apigenin is found to have protective effect of adult neurogenesis and for the treatment of neurological diseases, disorders and injuries, by stimulating the generation of neuronal cells in the adult brain. In addition, Apigenin readily crosses the blood-brain barrier and has not demonstrated toxicity at high doses. It could thus prevent amyloid beta deposition and tau phosphorylation due to neuroinflammation, which can lead to Alzheimer's disease.
WHY FARLONG® LIFEFLOWER® BREVISCAPINI™:
Farlong® Lifeflower® Breviscapini™ is a patented pharmaceutical grade Breviscapine.
U.S. Patent No.:6084080; China Patent No.: ZL 2011 1 0277789.1; ZL 2009 1 0163211.6.
QUALITY CONTROL SEED-TO-SALE TRACEABILITY
GSP Logistic & Warehousing
Third Party Laboratory
Quality & Safety Guarantee
Human and animal clinical trials and toxicity studies of breviscapine have been completed to show the clinical results for the treatment of cerebral ischemia stroke, coronary heart disease or pectoris.
A study titled “Post-marketing Safety Surveillance of Breviscapine Powder-Injection: a Registry Study” by Zhong Wang from China Academy of Chinese Medial Sciences has started in September 2015 and is currently in progress with 20,000 subjects enrolled.
Wang, WW et al. "Scutellarin May Alleviate Cognitive Deficits in a Mouse Model of Hypoxia by Promoting Proliferation and Neuronal Differentiation of Neural Stem Cells.". Iran J Basic Med Sci 20.3 (2017): 272-279.
Pengyue, Zhang et al. "Breviscapine Confers a Neuroprotective Efficacy against Transient Focal Cerebral Ischemia by Attenuating Neuronal and Astrocytic Autophagy in the Penumbra". Biomedicine & Pharmacotherapy 90 (2017): 69-76.
Wang, Wenjuan et al. "Neuroprotective Effect of Scutellarin on Ischemic Cerebral Injury by Down-Regulating the Expression of Angiotensin-Converting Enzyme and AT1 Receptor". PLOS ONE 11.1 (2016): e0146197.